Establish a Trust Fund for Science Research

President Reagan has proposed doubling the National Science Foundation (NSF) basic research budget by 1992. Equally important, he states in his budget message: "The Nation's future position in global markets will depend upon: the allocation of national resources to the generation of new knowledge; and the effective and timely transfer of this new knowledge to specific applications." This noble statement could as easily have been made by countless senators or representatives. Despite these noble

Written byPhilip Speser
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Despite these noble sentiments, there remain grounds for concern over the future of American science. While expressing equally noble views, the 99th Congress managed to cut general science 4.2 percent below the Administration's recommended level—thereby harming "blue sky" basic research like that which led to the revolutions in biotechnology and optics. While cuts in the recommended levels for NSF were taking place, the President was silent. Nor was much progress made by our elected officials on solving infrastructure problems such as obsolete university research facilities or lack of universal literacy.

One hundred years of experience demonstrate that science infrastructural needs are consistently shortchanged. If we are to address such needs we must find a supplemental source of funds for science.

One source of funds would be a Science Trust Fund. A tax of one-tenth of one percent on information (both printed and electronic) collected from producers or distributors would generate ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies